University of California San Diego, La Jolla, California.
Pneumology Department, University Hospitals of Leuven, Leuven, Belgium.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D92-9. doi: 10.1016/j.jacc.2013.10.024.
Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed numerous and exciting developments in chronic thromboembolic pulmonary hypertension (CTEPH). Emerging clinical data and advances in technology have led to reinforcing and updated guidance on diagnostic approaches to pulmonary hypertension, guidelines that we hope will lead to better recognition and more timely diagnosis of CTEPH. We have new data on treatment practices across international boundaries as well as long-term outcomes for CTEPH patients treated with or without pulmonary endarterectomy. Furthermore, we have expanded data on alternative treatment options for select CTEPH patients, including data from multiple clinical trials of medical therapy, including 1 recent pivotal trial, and compelling case series of percutaneous pulmonary angioplasty. Lastly, we have garnered more experience, and on a larger international scale, with pulmonary endarterectomy, which is the treatment of choice for operable CTEPH. This report overviews and highlights these important interval developments as deliberated among our task force of CTEPH experts and presented at the 2013 World Symposium on Pulmonary Hypertension in Nice, France.
自 2008 年上一届世界肺高血压研讨会以来，我们见证了慢性血栓栓塞性肺高血压（CTEPH）领域诸多激动人心的进展。新出现的临床数据和技术进步为肺高血压的诊断方法提供了强化和更新的指导，我们希望这些指导能够更好地识别和更及时地诊断 CTEPH。我们有跨越国界的治疗实践的新数据，以及接受或不接受肺动脉内膜切除术治疗的 CTEPH 患者的长期结局数据。此外，我们还扩大了选择性 CTEPH 患者的其他治疗选择的数据，包括来自多个临床试验的药物治疗数据，包括最近的一项关键试验，以及经皮肺动脉球囊扩张术的引人注目的病例系列。最后，我们在更大的国际范围内获得了更多的肺血管内膜切除术经验，肺血管内膜切除术是可手术治疗的 CTEPH 的首选治疗方法。本报告概述并强调了我们的 CTEPH 专家工作组审议的这些重要的间隔期进展，并在 2013 年法国尼斯举行的世界肺高血压研讨会上进行了介绍。
